Panitumumab

Drugs of Today

Volumn 42, Issue 11, 2006, Pages 711-719

  Chua, Yu Jo ^a   Cunningham, David ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEPHALOSPORIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TETRACYCLINE; UNINDEXED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON TUMOR; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEVER; HEAD AND NECK CANCER; HEADACHE; HICCUP; HUMAN; HYPERSENSITIVITY; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INSOMNIA; KIDNEY CANCER; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVARY TUMOR; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PANCREAS TUMOR; PAPULOPUSTULAR RASH; PARONYCHIA; PERIPHERAL EDEMA; PROSTATE CANCER; PROSTATE TUMOR; RASH; REVIEW; RIGOR; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TREATMENT FAILURE; TREATMENT RESPONSE; URTICARIA; VOMITING; WHEEZING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; EXANTHEMA; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846146343     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.11.1032061     Document Type: Review

References (45)

1. Cunningham, D., Humblet, Y., Siena, S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351: 337-45.
2. Moore, M.J., Goldstein, D., Hamm, J. et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 2005, 23: 1s, Abst. 1.
3. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335-42.
4. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344: 783-92.
5. Peeters, M., Van Cutsem, E., Siena, S. et al. A phase 3, multicenter, randomized controlled tial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the 97th American Association for Cancer Research Annual Meeting, Washington, D.C., 2006, Abst. CP-1.
6. Arteaga, C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002, 29: 3-9.
7. Yarden, Y., Sliwkowski, M.X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001, 2: 127-37.
8. Wu, X., Fan, Z., Masui, H., Rosen, N., Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995, 95: 1897-905.
9. Spano, J.P., Lagorce, C., Atlan, D. et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005, 16: 102-8.
10. Goldstein, N.S., Armin, M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001, 92: 1331-46.
11. Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19: 183-232.
12. Waksal, H.W. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999, 18: 427-36.
13. Ciardiello, F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000, 60 (Suppl. 1): 25-32; discussion 41-2.
14. Bonner, J.A., Harari, P.M., Giralt, J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354: 567-78.
15. Prewett, M.C., Hooper, A.T., Bassi, R., Ellis, L.M., Waksal, H.W., Hicklin, DJ. Enhancedantitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002, 8: 994-1003.
16. Perez-Soler, R., Delord, J.P., Halpern, A. et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005, 10: 345-56.
17. Perez-Soler, R., Saltz, L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 2005, 23: 5235-46.
18. Lacouture, M.E., Lai, S.E. The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006, 155: 852-4.
19. Saltz, L., Kies, M., Abbruzzese, J.L. et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003, 22: 204 (Abst. 817).
20. Segaert, S., Van Cutsem, E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16: 1425-33.
21. Schrag, D., Chung, K.Y., Flombaum, C., Saltz, L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005, 97: 1221-4.
22. Yang, X.D., Jia, X.C., Corvalan, J.R., Wang, P., Davis, C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38: 17-23.
23. Sandler, A.B. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park) 2006, 20: 35-40.
24. Yang, X.D., Jia, X.C., Corvalan, J.R., Wang, P., Davis, C.G., Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999, 59: 1236-43.
25. Foon, K.A., Yang, X.D., Weiner, L.M. et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004, 58: 984-90.
26. Lynch, D.H., Yang, X.D. Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002, 29: 47-50.
27. Bush, T., Freeman, D., Ogbagabriel, S. et al. Antitumor efficacy of panitumumab alone or in combination with chemotherapy against human pancreatic carcinoma xenografts. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia 2005, Abst. 2006247.
28. Wang, P., Fredlin, P., Davis, C.G., Yang, X.-D. Human anti-EGF receptor monoclonal antibody ABX-EGF: A potential therapeutic for the treatment of prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting, San Francisco 2002, Abst. 4525.
29. Figlin, R.A., Belldegrun, A.S., Crawford, J. et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), in patients with advanced cancer: Phase 1 clinical results. Proc Am Soc Clin Oncol 2002, 21: Abst. 35.
30. Rowinsky, E.K., Schwartz, G.H., Gollob, J.A. et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody, in patients with metastatic renal cell cancer. J Clin Oncol 2004, 22: 3003-15.
31. Arends, R., Yang, B., Schwab, G., Lockbaum, P., Funelas, C., Roskos, L. Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients. J Clin Oncol 2005, 23: Abst. 3089.
32. Weiner, L.M., Belldegrun, A.S., Rowinsky, E.K. et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol 2005, 23: Abst. 3059.
33. Hecht, J., Berlin, J., Malik, I. et al. Panitumumab therapy with irinotecan, 5-fluorouracil and leucovorin (IFL) in metastatic colorectal cancer (mCRC) patients: A pharmacokinetic (PK) analysis. Program and Proceedings of the 2005 Gastrointestinal Cancers Symposium, Hollywood, Florida, 2005, Abst. 259.
34. Malik, I., Hecht, J.R., Patnaik, A. et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005, 16s (June 1 suppl.): Abst. 3520.
35. Berlin, J., Neubauer, M., Swanson, P. et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing >10% epidermal growth factor receptor (EGFr). J Clin Oncol 2006, 24: Abst. 3548.
36. Hecht, J.R., Mitchell, E., Baranda, J. et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (<1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol 2006, 24: Abst. 3547.
37. Hecht, J., Posey, J., Tchekmedyian, S. et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Program and Proceedings of the 2006 Gastrointestinal Cancers Symposium, San Francisco 2006, Abst. 237.
38. Figlin, R., Bukowski, R., Srinivas, S. et al. A phase II trial of panitumumab (ABX-EGF) in the treatment of patients with metastatic renal cell carcinoma (mRCC). Proceedings of the 4th International Kidney Cancer Symposium, Chicago 2005.
39. Motzer, R.J., Bacik, J., Murphy, B.A., Russo, P., Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20: 289-96.
40. Crawford, J., Sandler, A.B., Hammond, L.A. et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2004, 22: Abst. 7083.
41. Crawford, J., Swanson, P., Prager, D. et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first-line advanced non-small-cell lung cancer (NSCLC): A primary analysis. Eur J Cancer 2005 (Suppl.), 3: 324.
42. Perez-Soler, R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003, 17: 23-8.
43. Lynch, T.J., Bell, D.W., Sordella, R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350: 2129-39.
44. Ellis, L.M., Hoff, P.M. Targeting the epidermal growth factor receptor: An important incremental step in the battle against colorectal cancer. J Clin Oncol 2004, 22: 1177-9.
45. Saif, M.W., Cohenuram, M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6: 118-24.